Noeleen Berkhout-Byrne1, Marije H Kallenberg1,2, André Gaasbeek1, Ton J Rabelink1, Sebastiaan Hammer3,4, Mark A van Buchem3, Matthias J van Osch3, Lucia J M Kroft3, Henk Boom5, Simon P Mooijaart2,6, Marjolijn van Buren1,7. 1. a Department of Nephrology , Leiden University Medical Center , Leiden , The Netherlands. 2. b Department of Gerontology and Geriatrics , Leiden University Medical Center , Leiden , The Netherlands. 3. c Department of Radiology , Leiden University Medical Center , Leiden , The Netherlands. 4. d Department of Radiology , HAGA Hospital , The Hague , The Netherlands. 5. e Department of Nephrology , Reinier de Graaf Group , Delft , The Netherlands. 6. f Institute for Evidence-based Medicine in Old Age (IEMO) , Leiden , The Netherlands. 7. g Department of Nephrology , HAGA Hospital , The Hague , The Netherlands.
Abstract
BACKGROUND: Older patients with end stage renal disease (ESRD) are at increased risk for cognitive decline, but detailed studies of the magnitude of cognitive decline on dialysis or comprehensive conservative management (CCM) are lacking and the underlying pathophysiological mechanisms have poorly been studied. OBJECTIVES: To describe the rationale and design of the COPE study. Study objectives are as follows. Firstly, to examine the severity of cognitive impairment in older patients reaching ESRD before dialysis and the rate of decline after dialysis or CCM initiation. Secondly, to study the association of blood biomarkers for microvascular damage and MRI derived measurements of small vessel disease with the rate of cognitive decline. Thirdly, to examine to what extent cardiac function is related to brain structure and perfusion in patients reaching ESRD. Finally, to study the association of cognitive and functional capacity with quality of life in pre-dialysis patients, as well as after dialysis or CCM initiation. STUDY DESIGN AND METHODS: The COPE study is a prospective, multicenter cohort study in the Netherlands, including prevalent and incident pre-dialysis patients ≥65 years old with eGFR ≤20 ml/min/1.73 m2, awaiting either dialysis or CCM initiation. At baseline extensive data is collected including a comprehensive geriatric assessment and laboratory tests. Brain and cardiac MRI for analysis of structural and functional abnormalities are performed at baseline and repeated following therapy change. All other measurements are repeated annually during four years of follow up, including an extra evaluation six months after initiation of dialysis. CONCLUSIONS: Knowledge of the magnitude of cognitive decline and its underlying pathophysiological mechanism, as well as its impact on functionality and quality of life can eventually help to postulate an algorithm for well balanced decision making in treatment strategies in older patients reaching ESRD. CLINICAL TRIAL REGISTRATION: The COPE study is registered on www.ccmo.nl (number: NL46389.058.13).
BACKGROUND: Older patients with end stage renal disease (ESRD) are at increased risk for cognitive decline, but detailed studies of the magnitude of cognitive decline on dialysis or comprehensive conservative management (CCM) are lacking and the underlying pathophysiological mechanisms have poorly been studied. OBJECTIVES: To describe the rationale and design of the COPE study. Study objectives are as follows. Firstly, to examine the severity of cognitive impairment in older patients reaching ESRD before dialysis and the rate of decline after dialysis or CCM initiation. Secondly, to study the association of blood biomarkers for microvascular damage and MRI derived measurements of small vessel disease with the rate of cognitive decline. Thirdly, to examine to what extent cardiac function is related to brain structure and perfusion in patients reaching ESRD. Finally, to study the association of cognitive and functional capacity with quality of life in pre-dialysis patients, as well as after dialysis or CCM initiation. STUDY DESIGN AND METHODS: The COPE study is a prospective, multicenter cohort study in the Netherlands, including prevalent and incident pre-dialysis patients ≥65 years old with eGFR ≤20 ml/min/1.73 m2, awaiting either dialysis or CCM initiation. At baseline extensive data is collected including a comprehensive geriatric assessment and laboratory tests. Brain and cardiac MRI for analysis of structural and functional abnormalities are performed at baseline and repeated following therapy change. All other measurements are repeated annually during four years of follow up, including an extra evaluation six months after initiation of dialysis. CONCLUSIONS: Knowledge of the magnitude of cognitive decline and its underlying pathophysiological mechanism, as well as its impact on functionality and quality of life can eventually help to postulate an algorithm for well balanced decision making in treatment strategies in older patients reaching ESRD. CLINICAL TRIAL REGISTRATION: The COPE study is registered on www.ccmo.nl (number: NL46389.058.13).
Entities:
Keywords:
Cognition; ESRD; dialysis; small vessel disease
Authors: Floor J van Deudekom; Marije H Kallenberg; Noeleen C Berkhout-Byrne; Gerard J Blauw; Henk Boom; Jeroen de Bresser; Mark A van Buchem; André Gaasbeek; Sebastiaan Hammer; Joep Lagro; Matthias J P van Osch; Marie-Noëlle Witjes-Ané; Ton J Rabelink; Marjolijn van Buren; Simon P Mooijaart Journal: BMC Nephrol Date: 2020-04-09 Impact factor: 2.388
Authors: Carlijn G N Voorend; Noeleen C Berkhout-Byrne; Yvette Meuleman; Simon P Mooijaart; Willem Jan W Bos; Marjolijn van Buren Journal: BMC Nephrol Date: 2021-01-06 Impact factor: 2.388
Authors: Qiao Zhao; Sabine J L Nooren; Laurien E Zijlstra; Jos J M Westenberg; Lucia J M Kroft; J Wouter Jukema; Noeleen C Berkhout-Byrne; Ton J Rabelink; Anton Jan van Zonneveld; Marjolijn van Buren; Simon P Mooijaart; Roel Bijkerk Journal: Noncoding RNA Date: 2022-01-10
Authors: Laurien E Zijlstra; Stella Trompet; J Wouter Jukema; Lucia J M Kroft; Jeroen de Bresser; Matthias J P van Osch; Sebastiaan Hammer; Marie-Noëlle Witjes; Marjolijn van Buren; Simon P Mooijaart Journal: Aging (Albany NY) Date: 2020-01-07 Impact factor: 5.682
Authors: Carlijn G N Voorend; Hanneke Joosten; Noeleen C Berkhout-Byrne; Adry Diepenbroek; Casper F M Franssen; Willem Jan W Bos; Marjolijn Van Buren; Simon P Mooijaart Journal: Eur Geriatr Med Date: 2021-04-19 Impact factor: 1.710